

ANTIGENICS INC /DE/  
Form 8-K  
October 03, 2006

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of  
The Securities Exchange Act of 1934

October 1, 2006

Date of Report (Date of earliest event reported)

---

**ANTIGENICS INC.**

(Exact name of registrant as specified in its charter)

---

**DELAWARE**  
(State or other jurisdiction

of incorporation)

**000-29089**  
(Commission File Number)

**06-1562417**  
(IRS Employer

Identification No.)

**630 Fifth Avenue, Suite 2100**

**New York, NY 10111**  
(Address of principal executive offices)

**212-994-8200**

**10111**  
(Zip Code)

(Registrant's telephone number, including area code)

## Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01** Entry into a Material Definitive Agreement

On September 13, 2006, the Compensation Committee of the Board of Directors of Antigenics Inc. (the Company ) approved a base salary of \$240,000 for Shalini Sharp, VP, CFO effective October 1, 2006 with a target bonus of 40%, which will be prorated, based the effective date of her appointment. In addition, Ms. Sharp was granted 60,000 options, with an exercise price of \$1.74, vesting in four equal annual installments beginning September 13, 2007.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ANTIGENICS INC.**

Date: October 3, 2006

By: /s/ Garo H. Armen  
Garo H. Armen, Ph.D.  
Chairman and Chief Executive Officer